India’s first COVID-19 vaccine candidate COVAXIN gets DCGI approval
Red Book
Red Book

Interview Guidance Program (IGP) for UPSC CSE 2024, Registrations Open Click Here to know more and registration

News: India’s first COVID-19 vaccine candidate COVAXIN has received the approval of Drug Controller General of India(DCGI) for phase I and II of human clinical trials.

Facts:

  • COVAXIN: It is an inactivated vaccine created from a strain of the infectious SARS-CoV-2 virus.
  • Developed by: It has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).

Additional Facts:

  • DGCI: It is a department of the Central Drugs Standard Control Organization(CDSCO) responsible for approval of licences of specified categories of drugs such as blood and blood products, IV fluids and vaccines in India.It comes under the Ministry of Health & Family Welfare.

Discover more from Free UPSC IAS Preparation Syllabus and Materials For Aspirants

Subscribe to get the latest posts sent to your email.

Print Friendly and PDF
Blog
Academy
Community